Jiangsu Vcare's Novel Drug Vicagrel Receives FDA Approval for Clinical Trials
Published Time:
2021-03-22 17:35
Source:
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced encouraging news regarding its novel antiplatelet drug Vicagrel: The US FDA has provided feedback on the company's submitted IND application for Vicagrel, permitting the company to initiate clinical trials.
Vicagrel has already completed Phase II clinical studies in China. Existing clinical trial results have demonstrated multiple advantages, including rapid onset of action, low dosage, no significant respiratory depression, low bleeding risk, and the design to overcome "clopidogrel resistance." Beyond its application in ACS, it has the potential to further expand its indications to include stroke patients, who are more sensitive to bleeding risks. Following FDA approval, we will initiate multiple international multi-center clinical studies.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "The IND approval for Vicagrel in the US marks a significant milestone in its clinical development program and the first step towards international expansion. We extend our gratitude to the Vcare team for their decade-long dedication and hard work. The previous Pre-IND meeting proceeded smoothly, with the FDA providing highly positive feedback and commendation for Vicagrel. Moving forward, we will collaborate closely with clinical trial sites and regulatory agencies to accelerate Vicagrel's development, striving to bring this more effective treatment option to cardiovascular disease patients as soon as possible."
About Vicagrel
Vicagrel is a collaborative industry-academia-research project between Jiangsu Vcare and China Pharmaceutical University. The company holds full rights and intellectual property for the project. Research findings have been successively published in several core domestic and international journals. The project was highlighted by SciBX (published by Nature), which rated Vicagrel as "one of the most commercially promising projects in this field of novel drugs."
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn